Resistentia Pharmaceuticals
Uppsala, Uppsala Lan, Sweden
About Resistentia Pharmaceuticals
Resistentia Pharmaceuticals, a biopharmaceutical company, develops immunotherapeutic products for allergic asthma and inflammatory disorders. It provides Immunoglobulin E for allergic reactions, including asthma, rhinitis, and dermatitis; and C5a for the treatment of inflammatory conditions, such as rheumatoid arthritis, asthma, and multiple sclerosis. Resistentia Pharmaceuticals AB was founded in 1998 and is based in Uppsala, Sweden.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Estimated revenue: $1K – $10K
- Total funding: $14.0M
- Funding stage: Late Stage Venture
- Last round: Series C (Sep 2006)
Industries & Categories
Biotechnology, Health Care, Medical Device, Therapeutics
Canonical: https://fsome.com/organization/resistentia-pharmaceuticals-2597526 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.